Abstract
Studies employing chemotherapy in early stage Hodgkin's disease suggest that this approach is at least comparable to radiation therapy in treatment outcome. Since the long-term disease-free survival in early stages approaches 90%, it is unlikely to further improve these results substantially. Thus, the major goal is the reduction of toxicity. The future choice of therapy will be influenced by the long-term toxicity of these approaches which has to be monitored carefully.